Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations

@article{Gambarin2009RationaleAD,
  title={Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations},
  author={Fabiana Isabella Gambarin and Valentina Favalli and Alessandra Serio and Mario B. Regazzi and Michele Pasotti and Catherine Klersy and Roberto Dore and Savina Mannarino and Mario Vigan{\'o} and Attilio Odero and Simona Amato and Luigi Tavazzi and Eloisa Arbustini},
  journal={Journal of Cardiovascular Medicine},
  year={2009},
  volume={10},
  pages={354–362}
}
Background The major clinical problem of Marfan syndrome (MFS) is the aortic root aneurysm, with risk of dissection when the root diameter approximates 5 cm. In MFS, a key molecule, transforming growth factor-β (TGF-β), normally bound to the extracellular matrix, is free and activated. In an experimental setting, TGF-β blockade prevents the aortic root structural damage and dilatation. The angiotensin receptor 1 blockers (sartanics) exert an anti-TGF-β effect; trials are now ongoing for… 

Figures and Tables from this paper

Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review.

The evidence for β-blocker therapy to reduce morbidity and mortality in Marfan syndrome is limited to a single small, prospective randomized and nonblinded clinical trial, suggesting that this study was underpowered to assess adverse aortic outcomes.

An evidence-based hypothesis for beneficial effects of telmisartan on Marfan syndrome.

Medical Treatment of Aortic Aneurysms in Marfan Syndrome and other Heritable Conditions

Currently used and promising medical treatment options for patients with heritable aortic aneurysmal disorders are reviewed and ongoing research will address the question whether such genotype/pathogenesis-driven treatments can replace current phenotype/syndrome-driven strategies and whether other forms of aortopathies should be treated similarly.

Atenolol versus losartan in children and young adults with Marfan's syndrome.

Among children and young adults with Marfan's syndrome who were randomly assigned to losartan or atenolol, it was found that there was no significant difference in the rate of aortic-root dilatation between the two treatment groups over a 3-year period.

Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial

A clinical benefit of combined losartan and β-blocker treatment in patients with MFS is suggested, suggesting a short follow-up period may be responsible for the low effect on clinical endpoints.
...

References

SHOWING 1-10 OF 76 REFERENCES

Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome

Losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with Marfan syndrome and has the potential to prevent the major life-threatening manifestation of this disorder.

Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial.

Perindopril reduced both aortic stiffness and aorti root diameter in patients with Marfan syndrome taking standard beta-blocker therapy, possibly through attenuation of TGF-beta signaling.

Effect of Angiotensin II Receptor Blocker on Plasma Levels of TGF-β1 and Interstitial Fibrosis in Hypertensive Kidney Transplant Patients

The study demonstrates that ARB significantly decreases the plasma levels of TGF-β1, proteinuria and uric acid, which could play an important and decisive role in the treatment and prevention of chronic allograft nephropathy.

Losartan improves resistance artery lesions and prevents CTGF and TGF-beta production in mild hypertensive patients.

The results show that the administration of losartan, but not amlodipine, to hypertensive patients improves structural abnormalities and prevents the production of CTGF and TGF-beta in small arteries, despite similar BP lowering.

Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients.

The study demonstrates that ARB significantly decreases the plasma levels of TGF-beta1, proteinuria and uric acid, which could play an important and decisive role in the treatment and prevention of chronic allograft nephropathy.

Nebivolol: A Third-Generation β-Adrenergic Blocker

Nebivolol is a novel β-adrenergic blocker that possesses unique pharmacologic properties, compared with other agents in its class, and appears to be as effective as other antihypertensive agents at lowering blood pressure and possesses benefits for patients with heart failure.

Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy

It is suggested that losartan has the potential to reverse or attenuate interstitial fibrosis, a major predictor of sudden cardiac death, in human patients with HCM.
...